BRISTOL-MYERS SQUIBB CO (BMY) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BMY - US1101221083 - Common Stock
54.5 USD
+0.28 (+0.52%)
54.57 USD
+0.07 (+0.13%)
Overall BMY gets a fundamental rating of 6 out of 10. We evaluated BMY against 191 industry peers in the Pharmaceuticals industry. While BMY has a great profitability rating, there are some minor concerns on its financial health. BMY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. BMY also has an excellent dividend rating. These ratings would make BMY suitable for value and dividend investing!
1. Profitability
1.1 Basic Checks
- In the past year BMY was profitable.
- In the past year BMY had a positive cash flow from operations.
- In multiple years BMY reported negative net income over the last 5 years.
- In the past 5 years BMY always reported a positive cash flow from operatings.
1.2 Ratios
- BMY's Return On Assets of 6.23% is amongst the best of the industry. BMY outperforms 87.43% of its industry peers.
- BMY has a better Return On Equity (32.55%) than 94.76% of its industry peers.
- The Return On Invested Capital of BMY (18.43%) is better than 95.81% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BMY is in line with the industry average of 12.84%.
- The 3 year average ROIC (12.30%) for BMY is below the current ROIC(18.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 18.43% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)12.3%
ROIC(5y)10.36%
1.3 Margins
- Looking at the Profit Margin, with a value of 12.57%, BMY belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
- BMY has a better Operating Margin (33.51%) than 95.29% of its industry peers.
- BMY's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 73.15%, BMY belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
- In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
- BMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, BMY has less shares outstanding
- Compared to 5 years ago, BMY has less shares outstanding
- BMY has a worse debt/assets ratio than last year.
2.2 Solvency
- BMY has an Altman-Z score of 2.23. This is not the best score and indicates that BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
- BMY has a Altman-Z score (2.23) which is comparable to the rest of the industry.
- BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as BMY would need 3.20 years to pay back of all of its debts.
- BMY has a better Debt to FCF ratio (3.20) than 87.96% of its industry peers.
- BMY has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
- BMY has a worse Debt to Equity ratio (2.41) than 79.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
ROIC/WACC2.09
WACC8.8%
2.3 Liquidity
- BMY has a Current Ratio of 1.27. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.27, BMY is doing worse than 78.01% of the companies in the same industry.
- A Quick Ratio of 1.17 indicates that BMY should not have too much problems paying its short term obligations.
- BMY has a Quick ratio of 1.17. This is in the lower half of the industry: BMY underperforms 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 460.68% over the past year.
- Measured over the past years, BMY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
- Looking at the last year, BMY shows a small growth in Revenue. The Revenue has grown by 1.26% in the last year.
- BMY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
- Based on estimates for the next years, BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 35.29% on average per year.
- BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.06% yearly.
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue Next Year0.23%
Revenue Next 2Y-3.95%
Revenue Next 3Y-3.2%
Revenue Next 5Y-5.06%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 8.31, the valuation of BMY can be described as very reasonable.
- Based on the Price/Earnings ratio, BMY is valued cheaper than 92.15% of the companies in the same industry.
- BMY is valuated cheaply when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 8.99, which indicates a very decent valuation of BMY.
- Based on the Price/Forward Earnings ratio, BMY is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.30, BMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.31 | ||
| Fwd PE | 8.99 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaper than 93.19% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMY indicates a rather cheap valuation: BMY is cheaper than 95.29% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.25 | ||
| EV/EBITDA | 6.78 |
4.3 Compensation for Growth
- BMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BMY has a very decent profitability rating, which may justify a higher PE ratio.
- BMY's earnings are expected to grow with 73.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y130.59%
EPS Next 3Y73.3%
5. Dividend
5.1 Amount
- BMY has a Yearly Dividend Yield of 4.45%, which is a nice return.
- Compared to an average industry Dividend Yield of 0.40, BMY pays a better dividend. On top of this BMY pays more dividend than 97.38% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.86, BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.45% |
5.2 History
- The dividend of BMY is nicely growing with an annual growth rate of 11.67%!
- BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
- BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- 82.81% of the earnings are spent on dividend by BMY. This is not a sustainable payout ratio.
- BMY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
54.5
+0.28 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-05 2026-02-05/amc
Inst Owners81.87%
Inst Owner Change0.12%
Ins Owners0.02%
Ins Owner Change-1.33%
Market Cap110.95B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts70
Price Target56.91 (4.42%)
Short Float %1.8%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.45% |
Yearly Dividend2.42
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02 2026-01-02 (0.63)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)6.03%
PT rev (3m)8.15%
EPS NQ rev (1m)-2.77%
EPS NQ rev (3m)1.7%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)1.81%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.31 | ||
| Fwd PE | 8.99 | ||
| P/S | 2.31 | ||
| P/FCF | 7.25 | ||
| P/OCF | 6.68 | ||
| P/B | 5.98 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.78 |
EPS(TTM)6.56
EY12.04%
EPS(NY)6.06
Fwd EY11.12%
FCF(TTM)7.52
FCFY13.79%
OCF(TTM)8.16
OCFY14.98%
SpS23.6
BVpS9.11
TBVpS-11.62
PEG (NY)0.02
PEG (5Y)N/A
Graham Number36.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 18.43% | ||
| ROICexc | 24.22% | ||
| ROICexgc | 123.43% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)12.3%
ROIC(5y)10.36%
ROICexc(3y)14.46%
ROICexc(5y)12.33%
ROICexgc(3y)78.95%
ROICexgc(5y)80.83%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.23 |
F-Score6
WACC8.8%
ROIC/WACC2.09
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.23%
Revenue Next 2Y-3.95%
Revenue Next 3Y-3.2%
Revenue Next 5Y-5.06%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.97%
EBIT Next 3Y49.92%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BMY.
What is the valuation status for BMY stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.
What is the profitability of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 7 / 10.
Can you provide the financial health for BMY stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to grow by 478.44% in the next year.